Biotricity, Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitoring sector of consumer healthcare, today announced its patent filing for the company's Bioheart device.
Company to report robust performance improvements in its operating metrics
Record Q1-FY2024 recurring revenue growth
Significantly higher margins on technology fees compared to blended margins
Strong control
Company estimates Q1-FY24 revenue to grow YOY by over 40%
Recurring technology fees, customer second-device sales, continue to trend higher
REDWOOD CITY, CA / ACCESSWIRE / July 6, 2023 / Biotricity
Gainers
Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in DRP-selected metastatic breast cancer patients.